

## THIS ISSUE'S AUTHORS

**SCOTT E. BOWEN, Ph.D.**, is an associate professor and area chair of the Behavioral and Cognitive Neuroscience Program within the Department of Psychology at Wayne State University (WSU). He is also an associate professor in WSU's Department of Obstetrics and Gynecology. His preclinical research is focused on behavioral pharmacology, behavioral toxicology, and neurobehavioral teratology. He investigates the acute and chronic behavioral effects of abused drugs, with a particular interest in volatile substances. Dr. Bowen's research also targets the development of a rodent model of prenatal misuse of volatile organic solvents (e.g., toluene).

**C. HENDRICKS BROWN, Ph.D.**, is a professor in the Department of Epidemiology and Public Health at the University of Miami Miller School of Medicine. Since 1985, he has received support from the National Institute of Mental Health and, more recently, from the NIDA to develop statistical methods for the design and analysis of preventive trials. As director of the Prevention Science and Methodology Group, Dr. Brown leads a network of methodologists who are working on the design of preventive field trials and their analysis, particularly with advanced techniques for growth analysis and for operating with missing data.

**MANORANJAN S. D'SOUZA, M.D., Ph.D.**, is a senior research fellow in the laboratory of Dr. Athina Markou at the University of California, San Diego School of Medicine. Dr. D'Souza's research focuses on understanding the neurobiology of nicotine dependence. In 2010, he received a fellowship from the Tobacco-Related Disease Research Program of the State of California to identify glutamatergic mechanisms involved in the extinction and reinstatement of nicotine-seeking behavior.

**ERIC GARLAND, Ph.D., L.C.S.W.**, is an assistant professor at the Florida State University College of Social Work and a research scholar of the Trinity Institute for the Addictions. As a post-doctoral fellow at the University of North Carolina at Chapel Hill School of Medicine, he conducted a randomized controlled pilot trial of a mindfulness-oriented recovery enhancement intervention for alcohol-dependent adults. Informed by years of clinical experience as a licensed psychotherapist, Dr. Garland's translational research agenda involves the development and testing of interventions that target the cognitive, affective, and psychophysiological mechanisms implicated in addictive disorders.

**MATTHEW O. HOWARD, Ph.D.**, is a professor at the University of North Carolina at Chapel Hill (UNC) School of Social Work and a research fellow at UNC's Cecil G. Sheps Center for Health Services Research. He has authored or coauthored 168 journal articles and has served as an editor, editorial board member, and reviewer for numerous journals and publishers. He is currently editor-in-chief of *Social Work Research*. Dr. Howard's research interests include inhalant use disorders, substance abuse and psychopathy among juvenile offenders, psychiatric disorders among inhalant users, and integration of evidence-based practices.

**SHEPPARD G. KELLAM, M.D.**, is professor emeritus and former chair of the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health. Since 1964, Dr. Kellam has designed, led, and collaborated in clinical and preventive trials conducted by interdisciplinary teams. His work in prevention research has contributed basic concepts such as the developmental epidemiological prevention research strategy

that has become a major focus of prevention research and is now playing a role in the transition from research to practice. He was the first president elected by the full membership of the Society for Prevention Research.

**ADELAIDE M. LANG, Ph.D.**, is a research project coordinator at Case Western Reserve University's Mandel School of Applied Social Sciences. Dr. Lang is a licensed clinical psychologist with over 20 years of experience working with children and families from high-risk populations. She has been a research staff member on Dr. Sonia Minnes' longitudinal study of prenatal cocaine exposure since 2003.

**ALEXANDRE B. LAUDET, Ph.D.**, is director of the Center for the Study of Addictions and Recovery at the National Development and Research Institutes, Inc. Her research focuses on elucidating patterns, processes, and psychosocial determinants of remission from substance use disorders, with the goal of informing service development and policy to create opportunities for long-term recovery and improved quality of life for people with these disorders. She serves on the editorial board of the *Journal of Substance Abuse Treatment* and of *Substance Use & Misuse* and provides consultancy to government agencies.

**AMELIA MACKENZIE, B.S.**, is a Master of Science student at the Johns Hopkins Bloomberg School of Public Health and a research assistant at the University of Maryland, School of Medicine, working in the fields of prevention science and reproductive health. Ms. Mackenzie has held leadership positions in the Women's Health Action Group and Health Leads. She is a member of the Delta Omega Honorary Society in Public Health.

**ATHINA MARKOU, Ph.D.**, a professor in the Department of Psychiatry, University of California, San Diego, has published about 150 journal articles and 40 book chapters. She is senior editor of *Neuropharmacology* and associate editor of *Neuroscience & Biobehavioral Reviews*. She received the Efron Award from the American College of Neuropsychopharmacology. Dr. Markou has been the principal investigator or director of several National Institutes of Health (NIH) grants, including a cooperative agreement on the discovery of GABAergic treatments for nicotine dependence. She has consulted with the United Nations, the World Health Organization, the NIH, and pharmaceutical companies.

**SONIA MINNES, Ph.D.**, is an assistant professor of social work at the Mandel School of Applied Social Sciences, Case Western Reserve University. Her research interests are child development and the pre- and postnatal factors that affect cognitive and mental health outcomes. Dr. Minnes is the principal investigator of a longitudinal study of prenatal cocaine exposure funded by NIDA. This study has followed a group of over 400 caregiver/child pairs since the children were born during 1994–1996. Dr. Minnes is currently assessing the study subjects as adolescents, evaluating their behavioral risk taking, initiation of substance use, development of mental health problems, and academic achievements.

**BRIAN PERRON, Ph.D.**, is an associate professor of social work at the University of Michigan. His research focuses on mental disorders and addiction, emphasizing services, clinical epidemiology, and psychometrics. He has active National Institutes of Health grants as a principal investigator, in addition to other projects funded by the State of Michigan and various centers of the University of Michigan. One of Dr. Perron's current projects involves examining the diagnostic formulation of inhalant use disorders, with an emphasis on withdrawal.

He is also involved in the education of social workers and social work researchers at both the master's and doctoral levels.

**HANNO PETRAS, Ph.D.**, is the associate director of research and development at JBS International, Inc., a company focused on understanding the health, social, and educational needs of people across their lifespan. His research interests and expertise are in the development of antisocial behavior, the design and evaluation of preventive interventions, and the appropriate application of statistical methods using latent variables. Dr. Petras serves on the board of directors for the Society for Prevention Research. He serves as the consulting editor for *Prevention Science* and is currently editing a book series that focuses on defining prevention science.

**JEANNE PODUSKA, Sc.D.**, is a managing researcher at the American Institutes for Research and director of the Center for Integrating Education and Prevention in Schools. She has the appointment of associate in the Johns Hopkins University Department of Mental Health. Dr. Poduska has worked at the intersection of public health, prevention, and education for the past 20 years, partnering with schools and districts to develop and test interventions aimed at early risk factors. Her recent work bridges effectiveness research and type 2 translational research with the goal of moving evidence-based programs into practice with high-quality fidelity.

**ALEXANDRA E. SHIELDS, Ph.D.**, is director of the Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities; associate professor of medicine at Harvard Medical School; associate faculty in molecular and population genetics at the Broad Institute; and codirector of the Harvard Catalyst Health Disparities Research Program. Dr. Shields' work addresses the challenges of clinical integration of new genomic medicine and technologies into clinical practice, with a particular

focus on the impact of these changes on minority and underserved populations. She also studies important ethical aspects of genomics research design, including the use of race constructs and the inclusion of environmental measures most important to understanding health disparities in gene-environment interaction studies.

**LYNN T. SINGER, Ph.D.**, is a professor of environmental health sciences, pediatrics, and psychiatry at Case Western Reserve University. She has directed numerous research programs, including a 19-year study of high-risk preterm infants, longitudinal studies of drug-exposed infants in Cleveland and London, and a National Science Foundation program to enhance the careers of women faculty in science and engineering. She has edited two books and has authored more than 125 articles in the medical and psychological literature. Dr. Singer serves on the governing council of the Neurobehavioral Teratology Society and on a committee of the National Institutes of Health Center for Scientific Review.

**MICHAEL G. VAUGHN, Ph.D.**, is an associate professor in the School of Social Work at Saint Louis University (SLU); he also holds appointments in SLU's Department of Public Policy Studies and in the Department of Community Health, School of Public Health. He has published more than 120 peer-reviewed articles and 25 book chapters. Dr. Vaughn's research interests include adolescent drug use and abuse in relation to antisocial behavior over the life course. Current projects include a cell-to-society approach to the study of human behavior, drug use, and gun carrying and drug use epidemiology of criminal justice populations.

**WEI WANG, Ph.D.**, is an assistant professor of biostatistics at the University of South Florida (USF). He has been the leading statistician in multiple prevention trials, including classroom and family-based

programs focused on reducing substance use and increasing academic performance. Dr. Wang has been a long-term member of the Prevention Science & Methodology Group, and he currently serves as the USF principal investigator for three federally funded grants.

**HOLLY C. WILCOX, Ph.D.**, has a joint faculty appointment as an assistant professor in the Johns Hopkins School of Medicine Department of Psychiatry as well as the School of Public Health Department of Mental Health. Dr. Wilcox is a psychiatric epidemiologist with a primary interest in the etiology and prevention of suicidal behaviors among young people. She is currently involved in a study of the etiology and pathways to suicide attempts among two cohorts of first-graders in Baltimore who participated in an intervention trial and were followed into adulthood. She also leads a study of early trauma exposure, hypothalamic-pituitary-adrenal axis function, and risk for suicide attempts among young people at familial risk for recurrent early-onset depression and is the Johns Hopkins principal investigator of a multisite genetic study of young people at risk for bipolar disorder.

#### ◻ & PANEL RESPONDENTS

**RICKA. BEVINS, Ph.D.**, is a professor and vice chair of psychology at the University of Nebraska–Lincoln. His research focuses on the use of animal models to elucidate neuropharmacological and behavioral factors involved in the etiology of drug abuse. He has authored or coauthored more than 100 articles, is an editor for the *Journal of the Experimental Analysis of Behavior*, and serves on the editorial advisory board of *ACS Chemical Neuroscience*.

**MARGARET S. CHISOLM, M.D.**, is an assistant professor of psychiatry and behavioral sciences at The Johns Hopkins University and a psychiatrist at the Center

for Addiction and Pregnancy at the Johns Hopkins Bayview Medical Center. Her primary research interest is the relationship between cigarette smoking, depression, and neonatal outcomes in drug-dependent pregnant patients. Dr. Chisolm is currently the primary investigator for a NIDA-supported study on pregnancy and drug abuse.

**VICTORIA H. COLEMAN-COWGER, Ph.D.**, is a research scientist for Chestnut Health Systems, a mental health and substance abuse treatment provider in Bloomington, Illinois. Her research focuses on smoking cessation and relapse prevention during pregnancy and postpartum. As an early-career investigator, Dr. Coleman-Cowger has published empirical papers in the areas of substance abuse, smoking cessation during pregnancy, telephone counseling, mental health, and women's health.

**DANNY H. HALL, Ph.D.**, is coordinator of the Intensive Outpatient Program at the John D. Dingell VA Medical Center in Detroit, Michigan. He is currently working on effectiveness research and his supervisory interests include disseminating research-based treatments for addiction and co-occurring disorders. Dr. Hall won an Early Career Investigator Awards at the American Psychological Association's conference in 2005. He has also published articles concerning addiction treatment and training.

**PAUL KENNY, Ph.D.**, is an associate professor in the Department of Molecular Therapeutics at The Scripps Research Institute. He also has a joint faculty appointment in the Kellogg School of Science and Technology. Dr. Kenny's research focuses on understanding the neurobiological mechanisms of drug addiction, obesity, and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors in these processes. Dr. Kenny is a member of the Board of Scientific Counselors for the NIDA Intramural Research Program.

**JED E. ROSE, Ph.D.**, is director of the Duke Center for Nicotine and Smoking Cessation Research and medical research professor in the Department of Psychiatry at Duke University Medical Center. Dr. Rose led the initial studies of transdermal nicotine administration, which helped pave the way for the development of commercial nicotine skin patches as a smoking cessation treatment. His current research uses brain imaging methodologies to identify brain substrates underlying craving and addiction.

**DAVE ROSS, Ph.D.**, is the clinical director of Behavioral Healthcare Services for Catholic Charities CYO in the San Francisco Bay Area. In addition to directing community-based mental health and substance abuse programs, Dr. Ross maintains a private practice. In his 35-year career, he has been clinical director for hospital-based chemical dependency programs and has trained interns to provide psychotherapy.

**LUCY ZAMMARELLI, M.A., NCAC II, CADC III**, is the clinical director at Willamette Family, Inc., a behavioral health care organization providing residential and outpatient services at six clinics in Eugene, Oregon. She serves on the National Child Traumatic Stress Network Steering Committee, where she co-chairs the Trauma and Substance Abuse Subcommittee. She also teaches in the University of Oregon's Substance Abuse Prevention Program, with a focus on trauma treatment and issues pertaining to families, veterans, and women.